MB, Levis & Associates’s Exelixis EXEL Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$54.4K Hold
1,000
0.02% 102
2026
Q1
$42.9K Hold
1,000
0.02% 107
2025
Q4
$43.8K Hold
1,000
0.02% 107
2025
Q3
$41.3K Hold
1,000
0.02% 109
2025
Q2
$44.1K Hold
1,000
0.02% 123
2025
Q1
$36.9K Hold
1,000
0.02% 137
2024
Q4
$33.3K Hold
1,000
0.02% 136
2024
Q3
$25.9K Hold
1,000
0.01% 150
2024
Q2
$22.5K Hold
1,000
0.01% 153
2024
Q1
$23.7K Sell
1,000
-1,500
-60% -$33.3K 0.01% 152
2023
Q4
$60K Sell
2,500
-500
-17% -$10.9K 0.03% 105
2023
Q3
$65.5K Hold
3,000
0.04% 98
2023
Q2
$57.3K Hold
3,000
0.04% 108
2023
Q1
$58.2K Hold
3,000
0.04% 108
2022
Q4
$48.1K Buy
+3,000
New +$48.9K 0.04% 107

Other funds holding EXEL

MB, Levis & Associates's EXEL Position: Q2 2026 in Review

MB, Levis & Associates held its Exelixis (EXEL) position steady in Q2 2026 at 1,000 shares worth $54.4K. The position accounts for 0.02% of the portfolio, ranked #102.

MB, Levis & Associates first reported a position in EXEL in Q4 2022 and has held it in 15 quarters since. The position peaked at $65.5K in Q3 2023. 253 funds tracked by Wall St. Rank hold EXEL as of Q2 2026.

  • MB, Levis & Associates held 1,000 shares of Exelixis worth $54.4K as of Q2 2026.
  • MB, Levis & Associates left its Exelixis share count unchanged in Q2 2026.
  • Exelixis made up 0.02% of MB, Levis & Associates's portfolio in Q2 2026, its #102 holding.
  • MB, Levis & Associates first reported a position in Exelixis in Q4 2022 and has held it in 15 quarters since.
  • MB, Levis & Associates's Exelixis position peaked at $65.5K in Q3 2023.
  • 253 funds tracked by Wall St. Rank held Exelixis as of Q2 2026.

Based on MB, Levis & Associates's 13F filing for Q2 2026, filed 22 Jul 2026.